Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Lambertini

Showing results (271-280 of 375) with videos related to

Pageof 38
Sort By:
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
Clinical Breast Cancer|November 19, 2019
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational StudyBenedetta Conte, Alessandra Fabi, Francesca Poggio, et al.
Journal of the National Cancer Institute|August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patientsMatteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.
Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.
Cancer|October 19, 2018
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.
Eclinicalmedicine|October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendationsAlberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trialBenedetta Conte, Marco Bruzzone, Matteo Lambertini, et al.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
The Lancet. Oncology|February 1, 2024
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendationsIcro Meattini, Carlotta Becherini, Saverio Caini, et al.
Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.
Pageof 38

Showing results (271-280 of 375) with videos related to

Sort By:
Pageof 38
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
Clinical Breast Cancer|November 19, 2019
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational StudyBenedetta Conte, Alessandra Fabi, Francesca Poggio, et al.
Journal of the National Cancer Institute|August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patientsMatteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.
Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.
Cancer|October 19, 2018
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.
Eclinicalmedicine|October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendationsAlberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trialBenedetta Conte, Marco Bruzzone, Matteo Lambertini, et al.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
The Lancet. Oncology|February 1, 2024
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendationsIcro Meattini, Carlotta Becherini, Saverio Caini, et al.
Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.
Pageof 38